ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer
Adding the tablet capecitabine to gemcitabine after surgery for pancreatic cancer lengthened median survival by about two and a half months with little extra toxicity, giving patients who cannot manage FOLFIRINOX a better option than gemcitabine alone.
Overview
Open-label randomised phase 3 trial by the European Study Group for Pancreatic Cancer in 730 patients from 92 hospitals who had undergone complete macroscopic resection of pancreatic ductal adenocarcinoma. Patients received six cycles of gemcitabine alone or gemcitabine plus oral capecitabine.
Median overall survival was 28.0 months with the combination against 25.5 months with gemcitabine alone (hazard ratio 0.82). Five-year survival was higher with the combination, and grade 3 or 4 adverse events were similar between the arms apart from more hand-foot syndrome and diarrhoea with capecitabine.
- Median overall survival 28.0 versus 25.5 months, hazard ratio 0.82.
- Toxicity was similar overall, with more hand-foot syndrome and diarrhoea in the combination arm.
Gemcitabine plus capecitabine became the adjuvant regimen for patients unfit for modified FOLFIRINOX, and remains the comparator in European trials of adjuvant treatment.
- The absolute gain was modest and PRODIGE 24 soon showed a much larger benefit from modified FOLFIRINOX in fitter patients.
- Many patients had R1 resections, so the trial population differs from strictly R0 series.
Similar pages
not linked directly; found by shared links- TrialSafety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma.
- Key paperESPAC5: immediate surgery versus short-course neoadjuvant chemotherapy or chemoradiotherapy for borderline resectable pancreatic cancer
Shares Capecitabine, Gemcitabine, Pancreatic ductal adenocarcinoma.
- Key paperPREOPANC long-term results: neoadjuvant gemcitabine-based chemoradiotherapy versus upfront surgery for resectable and borderline resectable pancreatic cancer
Shares Resectable pancreatic ductal adenocarcinoma, Gemcitabine, Pancreatic ductal adenocarcinoma.
- Key paperLAP07: chemoradiotherapy versus continued chemotherapy for locally advanced pancreatic cancer controlled after four months of gemcitabine
Shares Capecitabine, Gemcitabine, Pancreatic ductal adenocarcinoma.
- TrialStudy of Combined SGT-53 Plus Gemcitabine/Nab-Paclitaxel for Metastatic Pancreatic Cancer
- TrialEvaluation of Safety and Efficacy in BEY1107 in Monotherapy Gemcitabine Combination in Patient with Pancreatic Cancer
- TrialPolymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer
- TrialANO31905 in Combination With Chemotherapy for CLDN18.2-Positive Locally Advanced Unresectable or Metastatic Pancreatic Cancer